PolyPid director granted 9,132 stock options

Stein Robert Benjamin reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 07/17/2026 - 04:03 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Stein Robert Benjamin reported acquisition or exercise transactions in this Form 4 filing.

PolyPid Ltd. director Robert Benjamin Stein received a grant of 9,132 stock options to purchase Ordinary Shares at $4.46 per share. The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030 and expire on July 15, 2036. Following this grant, he holds 9,132 options directly.

Insider Trade Summary

Grant/Award: 9,132 shares

Grant/Award 1 txn

Insider Stein Robert Benjamin

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy) F1	9,132	$4.46	$41K

Holdings After Transaction: Stock option (right to buy) — 9,132 contracts (Direct)

Holdings Before and After: Stock option (right to buy), 0 to 9,132 contracts (Direct)

Footnotes (1)

1. F1. The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030.

Key Figures

Stock options granted: 9,132 options Exercise price: $4.46 per share Underlying shares: 9,132 Ordinary Shares +3 more

6 metrics

Stock options granted 9,132 options Stock option grant on July 15, 2026 to director Robert Benjamin Stein

Exercise price $4.46 per share Conversion or exercise price for the 9,132 stock options

Underlying shares 9,132 Ordinary Shares Each option is exercisable into one Ordinary Share

Expiration date July 15, 2036 Expiration date of the granted stock options

Vesting period end April 15, 2030 Options vest on a quarterly basis until April 15, 2030

Options held after grant 9,132 options Total derivative securities beneficially owned following the transaction

Key Terms

Stock option (right to buy), conversion or exercise price, expiration date, Ordinary Shares, +1 more

5 terms

Stock option (right to buy) financial

"Security title is listed as "Stock option (right to buy)" for the transaction"

conversion or exercise price financial

"The conversion or exercise price for the options is reported as $4.4600"

expiration date financial

"The expiration date for the stock option grant is July 15, 2036"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Ordinary Shares financial

"Each option is an underlying security titled as Ordinary Shares of PolyPid Ltd."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

vest on a quarterly basis financial

"The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PolyPid (PYPD) report for Robert Benjamin Stein?

PolyPid reported that director Robert Benjamin Stein was granted 9,132 stock options on July 15, 2026 at an exercise price of $4.46 per share. Each option is exercisable into one Ordinary Share, increasing his directly held option position to 9,132 options.

What is the exercise price of the new PolyPid (PYPD) stock options granted to Robert Benjamin Stein?

The new stock options for Robert Benjamin Stein carry an exercise price of $4.46 per share. This price applies to all 9,132 options, each of which is exercisable into one Ordinary Share if and when the options are vested and exercised.

How do the 9,132 PolyPid (PYPD) stock options granted to Robert Benjamin Stein vest?

The 9,132 options granted to Robert Benjamin Stein vest on a quarterly basis beginning July 15, 2026. Vesting continues through April 15, 2030, meaning portions of the award become exercisable over this multi‑year period rather than all at once.

When do Robert Benjamin Stein’s PolyPid (PYPD) stock options expire?

The stock options granted to Robert Benjamin Stein expire on July 15, 2036 if not exercised. After this expiration date, any unexercised options from this 9,132‑unit grant will no longer be exercisable into PolyPid Ordinary Shares.

How many PolyPid (PYPD) options does Robert Benjamin Stein hold after this grant?

Following the reported grant, Robert Benjamin Stein beneficially owns 9,132 stock options directly. This total reflects the entire new award, as indicated by the post‑transaction holdings figure for derivative securities in the insider transaction report.

Was Robert Benjamin Stein’s PolyPid (PYPD) option grant made under a Rule 10b5-1 trading plan?

The report indicates the transaction was not affirmed as made under a Rule 10b5-1 plan, as the related checkbox is marked false. The disclosure instead classifies the event as a grant or award acquisition of derivative securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stein Robert Benjamin

(Last) (First) (Middle)

C/O POLYPID LTD.

18 HASIVIM STREET ISRAEL

(Street)

PETACH TIKVA 495376

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
PolyPid Ltd. [ PYPD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$4.46	07/15/2026		A		9,132		10/15/2026(1)	07/15/2036	Ordinary Shares	9,132	$4.46	9,132	D

Explanation of Responses:

1. The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030.

	/s/ Stein Robert Benjamin	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)